Clinica Chimica Acta:全面的免疫复合物分析可检测源自不育男性和女性的精浆和卵泡液中的疾病特异性免疫复合物抗原

2019-10-17 gladiator MedSci原创

自身免疫性反应和后续的炎症可能是精原性功能障碍和子宫内膜异位症相关不孕的病因。

自身免疫性反应和后续的炎症可能是精原性功能障碍和子宫内膜异位症相关不孕的病因。本研究的目的是在精浆(SP)和卵泡液(FF)免疫复合物(ICs)中鉴定疾病特异性抗原。

采用纳米液相色谱-串联质谱联用技术,对不育夫妇辅助生殖标本进行免疫复合体分析,综合鉴定生物体液中集成到ICs中的抗原。42名男性患者,包括少精症(n = 6),弱精子症(n = 8)和精液分析正常患者(n = 28)。58名女性患者,包括卵巢子宫内膜异位症患者(n = 10)和无疾病对照女性(n = 48)。

研究在少精子症患者中发现了4种疾病特异性抗原,而在弱精子症患者中发现了5种疾病特异性抗原,其中一些抗原参与了精子发生。仅在子宫内膜异位症患者中检测到8种抗原。

研究发现了与男性和女性不育的发病机制相对应疾病特异性抗原的功能特征。ICs的形成可能通过相关蛋白功能的丧失而导致精原性功能障碍和子宫内膜异位症相关不孕。免疫复合物分析有望成为研究不孕症新诊断方法和治疗策略的一个有价值的工具。

原始出处:

Naoko MurakamiMichio KitajimaComprehensive immune complexome analysis detects disease-specific immune complex antigens in seminal plasma and follicular fluids derived from infertile men and women

本文系梅斯医学(MedSci)原创编译整理,转载需授权!


版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1741219, encodeId=67db1e41219ca, content=<a href='/topic/show?id=62b636895ae' target=_blank style='color:#2F92EE;'>#卵泡#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36895, encryptionId=62b636895ae, topicName=卵泡)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7c3834890395, createdName=12498e87m50暂无昵称, createdTime=Mon Jul 27 10:02:00 CST 2020, time=2020-07-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1910646, encodeId=1f40191064617, content=<a href='/topic/show?id=b45b426195e' target=_blank style='color:#2F92EE;'>#复合物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42619, encryptionId=b45b426195e, topicName=复合物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ad7f282, createdName=yang0210, createdTime=Fri Feb 07 06:02:00 CST 2020, time=2020-02-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1849760, encodeId=ba241849e60d2, content=<a href='/topic/show?id=61815385aa' target=_blank style='color:#2F92EE;'>#CTA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5385, encryptionId=61815385aa, topicName=CTA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ec9955, createdName=windight, createdTime=Sat Nov 09 04:02:00 CST 2019, time=2019-11-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1899331, encodeId=2f3f18993313b, content=<a href='/topic/show?id=6f746e94170' target=_blank style='color:#2F92EE;'>#特异性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=67941, encryptionId=6f746e94170, topicName=特异性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=dc7a157, createdName=jinweidong, createdTime=Mon Nov 11 09:02:00 CST 2019, time=2019-11-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1522258, encodeId=71ba15222587c, content=<a href='/topic/show?id=83732900161' target=_blank style='color:#2F92EE;'>#免疫复合物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=29001, encryptionId=83732900161, topicName=免疫复合物)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=311711435936, createdName=zhaohui6735, createdTime=Sat Oct 19 13:02:00 CST 2019, time=2019-10-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1623349, encodeId=2040162334947, content=<a href='/topic/show?id=62a655263e9' target=_blank style='color:#2F92EE;'>#抗原#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55263, encryptionId=62a655263e9, topicName=抗原)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f59b20519025, createdName=xiaoyeshuang, createdTime=Sat Oct 19 13:02:00 CST 2019, time=2019-10-19, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1741219, encodeId=67db1e41219ca, content=<a href='/topic/show?id=62b636895ae' target=_blank style='color:#2F92EE;'>#卵泡#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36895, encryptionId=62b636895ae, topicName=卵泡)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7c3834890395, createdName=12498e87m50暂无昵称, createdTime=Mon Jul 27 10:02:00 CST 2020, time=2020-07-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1910646, encodeId=1f40191064617, content=<a href='/topic/show?id=b45b426195e' target=_blank style='color:#2F92EE;'>#复合物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42619, encryptionId=b45b426195e, topicName=复合物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ad7f282, createdName=yang0210, createdTime=Fri Feb 07 06:02:00 CST 2020, time=2020-02-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1849760, encodeId=ba241849e60d2, content=<a href='/topic/show?id=61815385aa' target=_blank style='color:#2F92EE;'>#CTA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5385, encryptionId=61815385aa, topicName=CTA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ec9955, createdName=windight, createdTime=Sat Nov 09 04:02:00 CST 2019, time=2019-11-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1899331, encodeId=2f3f18993313b, content=<a href='/topic/show?id=6f746e94170' target=_blank style='color:#2F92EE;'>#特异性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=67941, encryptionId=6f746e94170, topicName=特异性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=dc7a157, createdName=jinweidong, createdTime=Mon Nov 11 09:02:00 CST 2019, time=2019-11-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1522258, encodeId=71ba15222587c, content=<a href='/topic/show?id=83732900161' target=_blank style='color:#2F92EE;'>#免疫复合物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=29001, encryptionId=83732900161, topicName=免疫复合物)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=311711435936, createdName=zhaohui6735, createdTime=Sat Oct 19 13:02:00 CST 2019, time=2019-10-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1623349, encodeId=2040162334947, content=<a href='/topic/show?id=62a655263e9' target=_blank style='color:#2F92EE;'>#抗原#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55263, encryptionId=62a655263e9, topicName=抗原)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f59b20519025, createdName=xiaoyeshuang, createdTime=Sat Oct 19 13:02:00 CST 2019, time=2019-10-19, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1741219, encodeId=67db1e41219ca, content=<a href='/topic/show?id=62b636895ae' target=_blank style='color:#2F92EE;'>#卵泡#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36895, encryptionId=62b636895ae, topicName=卵泡)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7c3834890395, createdName=12498e87m50暂无昵称, createdTime=Mon Jul 27 10:02:00 CST 2020, time=2020-07-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1910646, encodeId=1f40191064617, content=<a href='/topic/show?id=b45b426195e' target=_blank style='color:#2F92EE;'>#复合物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42619, encryptionId=b45b426195e, topicName=复合物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ad7f282, createdName=yang0210, createdTime=Fri Feb 07 06:02:00 CST 2020, time=2020-02-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1849760, encodeId=ba241849e60d2, content=<a href='/topic/show?id=61815385aa' target=_blank style='color:#2F92EE;'>#CTA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5385, encryptionId=61815385aa, topicName=CTA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ec9955, createdName=windight, createdTime=Sat Nov 09 04:02:00 CST 2019, time=2019-11-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1899331, encodeId=2f3f18993313b, content=<a href='/topic/show?id=6f746e94170' target=_blank style='color:#2F92EE;'>#特异性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=67941, encryptionId=6f746e94170, topicName=特异性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=dc7a157, createdName=jinweidong, createdTime=Mon Nov 11 09:02:00 CST 2019, time=2019-11-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1522258, encodeId=71ba15222587c, content=<a href='/topic/show?id=83732900161' target=_blank style='color:#2F92EE;'>#免疫复合物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=29001, encryptionId=83732900161, topicName=免疫复合物)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=311711435936, createdName=zhaohui6735, createdTime=Sat Oct 19 13:02:00 CST 2019, time=2019-10-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1623349, encodeId=2040162334947, content=<a href='/topic/show?id=62a655263e9' target=_blank style='color:#2F92EE;'>#抗原#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55263, encryptionId=62a655263e9, topicName=抗原)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f59b20519025, createdName=xiaoyeshuang, createdTime=Sat Oct 19 13:02:00 CST 2019, time=2019-10-19, status=1, ipAttribution=)]
    2019-11-09 windight
  4. [GetPortalCommentsPageByObjectIdResponse(id=1741219, encodeId=67db1e41219ca, content=<a href='/topic/show?id=62b636895ae' target=_blank style='color:#2F92EE;'>#卵泡#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36895, encryptionId=62b636895ae, topicName=卵泡)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7c3834890395, createdName=12498e87m50暂无昵称, createdTime=Mon Jul 27 10:02:00 CST 2020, time=2020-07-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1910646, encodeId=1f40191064617, content=<a href='/topic/show?id=b45b426195e' target=_blank style='color:#2F92EE;'>#复合物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42619, encryptionId=b45b426195e, topicName=复合物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ad7f282, createdName=yang0210, createdTime=Fri Feb 07 06:02:00 CST 2020, time=2020-02-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1849760, encodeId=ba241849e60d2, content=<a href='/topic/show?id=61815385aa' target=_blank style='color:#2F92EE;'>#CTA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5385, encryptionId=61815385aa, topicName=CTA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ec9955, createdName=windight, createdTime=Sat Nov 09 04:02:00 CST 2019, time=2019-11-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1899331, encodeId=2f3f18993313b, content=<a href='/topic/show?id=6f746e94170' target=_blank style='color:#2F92EE;'>#特异性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=67941, encryptionId=6f746e94170, topicName=特异性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=dc7a157, createdName=jinweidong, createdTime=Mon Nov 11 09:02:00 CST 2019, time=2019-11-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1522258, encodeId=71ba15222587c, content=<a href='/topic/show?id=83732900161' target=_blank style='color:#2F92EE;'>#免疫复合物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=29001, encryptionId=83732900161, topicName=免疫复合物)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=311711435936, createdName=zhaohui6735, createdTime=Sat Oct 19 13:02:00 CST 2019, time=2019-10-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1623349, encodeId=2040162334947, content=<a href='/topic/show?id=62a655263e9' target=_blank style='color:#2F92EE;'>#抗原#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55263, encryptionId=62a655263e9, topicName=抗原)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f59b20519025, createdName=xiaoyeshuang, createdTime=Sat Oct 19 13:02:00 CST 2019, time=2019-10-19, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1741219, encodeId=67db1e41219ca, content=<a href='/topic/show?id=62b636895ae' target=_blank style='color:#2F92EE;'>#卵泡#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36895, encryptionId=62b636895ae, topicName=卵泡)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7c3834890395, createdName=12498e87m50暂无昵称, createdTime=Mon Jul 27 10:02:00 CST 2020, time=2020-07-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1910646, encodeId=1f40191064617, content=<a href='/topic/show?id=b45b426195e' target=_blank style='color:#2F92EE;'>#复合物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42619, encryptionId=b45b426195e, topicName=复合物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ad7f282, createdName=yang0210, createdTime=Fri Feb 07 06:02:00 CST 2020, time=2020-02-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1849760, encodeId=ba241849e60d2, content=<a href='/topic/show?id=61815385aa' target=_blank style='color:#2F92EE;'>#CTA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5385, encryptionId=61815385aa, topicName=CTA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ec9955, createdName=windight, createdTime=Sat Nov 09 04:02:00 CST 2019, time=2019-11-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1899331, encodeId=2f3f18993313b, content=<a href='/topic/show?id=6f746e94170' target=_blank style='color:#2F92EE;'>#特异性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=67941, encryptionId=6f746e94170, topicName=特异性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=dc7a157, createdName=jinweidong, createdTime=Mon Nov 11 09:02:00 CST 2019, time=2019-11-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1522258, encodeId=71ba15222587c, content=<a href='/topic/show?id=83732900161' target=_blank style='color:#2F92EE;'>#免疫复合物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=29001, encryptionId=83732900161, topicName=免疫复合物)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=311711435936, createdName=zhaohui6735, createdTime=Sat Oct 19 13:02:00 CST 2019, time=2019-10-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1623349, encodeId=2040162334947, content=<a href='/topic/show?id=62a655263e9' target=_blank style='color:#2F92EE;'>#抗原#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55263, encryptionId=62a655263e9, topicName=抗原)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f59b20519025, createdName=xiaoyeshuang, createdTime=Sat Oct 19 13:02:00 CST 2019, time=2019-10-19, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=1741219, encodeId=67db1e41219ca, content=<a href='/topic/show?id=62b636895ae' target=_blank style='color:#2F92EE;'>#卵泡#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36895, encryptionId=62b636895ae, topicName=卵泡)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7c3834890395, createdName=12498e87m50暂无昵称, createdTime=Mon Jul 27 10:02:00 CST 2020, time=2020-07-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1910646, encodeId=1f40191064617, content=<a href='/topic/show?id=b45b426195e' target=_blank style='color:#2F92EE;'>#复合物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42619, encryptionId=b45b426195e, topicName=复合物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ad7f282, createdName=yang0210, createdTime=Fri Feb 07 06:02:00 CST 2020, time=2020-02-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1849760, encodeId=ba241849e60d2, content=<a href='/topic/show?id=61815385aa' target=_blank style='color:#2F92EE;'>#CTA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5385, encryptionId=61815385aa, topicName=CTA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ec9955, createdName=windight, createdTime=Sat Nov 09 04:02:00 CST 2019, time=2019-11-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1899331, encodeId=2f3f18993313b, content=<a href='/topic/show?id=6f746e94170' target=_blank style='color:#2F92EE;'>#特异性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=67941, encryptionId=6f746e94170, topicName=特异性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=dc7a157, createdName=jinweidong, createdTime=Mon Nov 11 09:02:00 CST 2019, time=2019-11-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1522258, encodeId=71ba15222587c, content=<a href='/topic/show?id=83732900161' target=_blank style='color:#2F92EE;'>#免疫复合物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=29001, encryptionId=83732900161, topicName=免疫复合物)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=311711435936, createdName=zhaohui6735, createdTime=Sat Oct 19 13:02:00 CST 2019, time=2019-10-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1623349, encodeId=2040162334947, content=<a href='/topic/show?id=62a655263e9' target=_blank style='color:#2F92EE;'>#抗原#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55263, encryptionId=62a655263e9, topicName=抗原)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f59b20519025, createdName=xiaoyeshuang, createdTime=Sat Oct 19 13:02:00 CST 2019, time=2019-10-19, status=1, ipAttribution=)]

相关资讯

Cell Res:去泛素化酶家族特异性抑制剂开发新靶点

泛素化/去泛素化是一种动态的蛋白质双向修饰调控系统,在体内由泛素连接酶(E1-E2-E3)和去泛素化酶(DUB)家族分别负责。与磷酸化/去磷酸化系统类似,通过参与细胞内众多信号通路,泛素化双向修饰决定了很多生理事件的发生发展,被认为是极具潜力的癌症及神经类等疾病的治疗新靶点。

Arthritis Rheumatol:中轴型脊柱关节炎中抗CD74自身抗体的敏感性和特异性

抗CD74 IgA是识别axSpA的有用工具。测试的诊断价值需要在日常实践中进一步证明。

转录辅助因子对不同类型的核心启动子具有特异性

转录辅助因子(transcriptional cofactor, COF)在增强子与启动子之间传递调控线索,是转录激活和基因表达的核心效应物。虽然已证实某些COF比其他COF更偏好某些启动子类型,但是不同COF对不同启动子显示出的内在特异性的程度尚不清楚。

Cell Res:薛愿超组揭示胞苷脱氨酶AID特异性识别靶位点的新机制

抗体多样性的产生对人类健康至关重要。当机体受到病原菌侵染后,外周免疫器官中的B细胞会大量表达胞苷脱氨酶基因AID(Activation-induced cytidine deaminase)。当AID结合到免疫球蛋白基因的可变区后会将单链DNA中的胞嘧啶脱氨化为尿嘧啶核苷,进而借助机体的损伤修复机制在可变区产生高频突变以筛选出具有高亲和力的抗体。与此同时,AID会结合到免疫球蛋白基因的转换区进而介

Ann Rheum Dis :MRI检测到的侵蚀是RA特异性的吗?

个人患者的总侵蚀评分大部分存在重叠。在诊断过程中不要高估MRI侵蚀的价值。

J Clin Periodontol:部分口腔检测下牙周病错误分类的机制的评价

评估使用部分口腔记录(PMR)的假设以及牙周病潜在错误分类的相关机制。